<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000690369"><TermName>Halaven</TermName><TermPronunciation>(HA-lih-ven)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat metastatic breast cancer in patients who have already been treated with other chemotherapy. It is also being studied in the treatment of other types of cancer. Halaven may block cancer cell growth by stopping cell division. It belongs to the family of drugs called antitubulin agents. Also called E7389 and eribulin mesylate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000727544" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Halaven&quot;" language="en" id="_3"/><MediaLink ref="CDR0000727543" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Halaven&quot;" language="es" id="_4"/><SpanishTermName>Halaven</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar el cáncer de mama metastásico de pacientes que ya fueron tratados con otra quimioterapia. También está en estudio para el tratamiento de otros tipos de cáncer. Halaven puede evitar el crecimiento de las células cancerosas al impedir la multiplicación celular. Pertenece a la familia de los antitubulínicos. También se llama E7389 y mesilato de eribulina.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-12-10</DateFirstPublished><DateLastModified>2010-12-10</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000689690">Eribulin Mesylate</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
